Síndrome de Hiper IgD: espectros clínicos, achados genéticos e condutas terapêuticas
Hyper-IgD syndrome: clinical spectrum, genetic findings, and therapeutic approaches
Alex Isidoro Ferreira Prado; Fabio Fernandes Morato Castro; Jorge Kalil; Myrthes Toledo Barros; Leonardo Oliveira Mendonça
Resumo
A deficiência de mevalonato quinase (MVK; MIM #142680; ORPHA #343) é uma doença genética, espectral, rara, associadas a mutações ao longo do gene MVK causando distúrbios na síntese do colesterol, que culminam em: inflamação sistêmica com febre, adenopatia, sintomas abdominais e outros achados clínicos. Enquanto no polo leve da doença os achados mais comuns são febres recorrentes com linfadenopatia, no polo mais grave adiciona-se o acometimento do sistema nervoso central (meningites assépticas, vasculites e atraso do desenvolvimento neuropsicomotor) e do sistema hematopoiético (síndrome de ativação macrofágica). Apesar de inúmeras terapêuticas, os bloqueadores da interleucina-1 ainda são os únicos medicamentos capazes de controlar a doença e de impedir a evolução para amiloidose. Os estudos atuais visam tentar novos tratamentos, como o transplante de células-tronco hematopoiéticas, ou mesmo a terapia gênica.
Palavras-chave
Abstract
Mevalonate kinase deficiency (MVK; MIM #142680; ORPHA #343) is a rare spectral genetic disorder linked to mutations along the MVK gene leading to impaired cholesterol synthesis, clinically observed as systemic inflammation with fever, adenopathy, abdominal manifestations, and other clinical findings. While on mild forms recurrent fever with lymphadenopathy is commonly observed, severe forms add to that neurological (aseptic meningitis, vasculitis, and neuropsychomotor developmental delay) and hematopoietic involvement (macrophage activation syndrome). Despite of several therapeutic approaches, blocking interleukin-1 is the only effective method to control the disease and prevent the development of systemic amyloidosis. Ongoing studies aim to test new treatments, such as hematopoietic stem cell transplantation and gene therapy
Keywords
Referências
1. van der Meer JW, Vossen JM, Radl J, van Nieuwkoop JA, Meyer CJ, Lobatto S, et al. Hyperimmunoglobulinaemia D and periodic fever: a new syndrome. Lancet. 1984;1(8386):1087-90.
2. Favier LA, Schulert GS. Mevalonate kinase deficiency: current perspectives. Appl Clin Genet. 2016;9:101-10.
3. Gabor KA, Fessler MB. Roles of the mevalonate pathway and cholesterol trafficking in pulmonary host defense. Curr Mol Pharmacol. 2017;10(1):27-45.
4. van der Burgh R, Pervolaraki K, Turkenburg M, Waterham HR, Frenkel J, Boes M. Un-prenylated RhoA contributes to IL-1beta hypersecretion in mevalonate kinase deficiency model through stimulation of Rac1 activity. J Biol Chem. 2014;289(40):27757‑65.
5. Hoffmann GF, Charpentier C, Mayatepek E, Mancini J, Leichsenring M, Gibson KM, et al. Clinical and biochemical phenotype in 11 patients with mevalonic aciduria. Pediatrics. 1993;91(5):915-21.
6. van der Burgh R, Ter Haar NM, Boes ML, Frenkel J. Mevalonate kinase deficiency, a metabolic autoinflammatory disease. Clin Immunol. 2013;147(3):197-206.
7. Mandey SHL, Schneiders MS, Koster J, Waterham HR. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Human Mutation. 2006;27(8):796-802.
8. Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J. 2016;14(1):30.
9. Haraldsson A, Weemaes CM, De Boer AW, Bakkeren JA, Stoelinga GB. Immunological studies in the hyper-immunoglobulin D syndrome. J Clin Immunol. 1992;12(6):424-8.
10. van der Hilst JC, Bodar EJ, Barron KS, Frenkel J, Drenth JP, van der Meer JW, et al. Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore). 2008;87(6):301-10.
11. Signa S, Cerinic CM, Toniolo E, Bustaffa M, D’alessandro M, Volp S, et al. OP0260 Vaccination safety and coverage in an Italian cohort of autoinflammatory diseases. Ann Rheum Dis. 2019;78:211.
12. Padeh S, Berkun Y. Periodic fever syndromes. In: Shoenfeld Y, Cervera , Gershwin ME (eds.) Diagnostic Criteria in Autoimmune Diseases. Humana Press; 2008. p. 201-7.
13. Havnaer A, Han G. Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment. Am J Clin Dermatol. 2019;20(4):539-64.
14. Pieri C, Insalaco A, Taddio A, Barbi E, Lepore L, Tommasini A, et al. Mevalonate kinase deficiency: Various aspects of the same disease. Medico e Bambino. 2013;32:501-6.
15. Pieri C, Taddio A, Insalaco A, Barbi E, Lepore L, Ventura A, et al. Different presentations of mevalonate kinase deficiency: A case series. Clin Exp Rheumatol. 2015;33:437‑42.
16. Kastner DL. Hereditary periodic fever syndromes. Hematology. 2005;2005(1):74-81.
17. Ammouri W, Cuisset L, Rouaghe S, Rolland M-O, Delpech M, Grateau G, et al. Diagnostic value of serum immunoglobulinaemia D level in patients with a clinical suspicion of hyper IgD syndrome. Rheumatology. 2007;46(10):1597-600.
18. Pace S, Bingham J, Royer M. Histopathologic features in a case of hyperimmunoglobulinemia D syndrome. Indian Dermatol Online J. 2015;6(Suppl 1):S33-S6.
19. ter Haar N, Lachmann H, Özen S, Woo P, Uziel Y, Modesto C, et al. Treatment of auto-inflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013;72(5):678‑85.
20. Durel C-A, Aouba A, Bienvenu B, Deshayes S, Coppéré B, Gombert B, et al. Observa-tional Study of a French and Belgian Multicenter Cohort of 23 Patients Diagnosed in Adulthood With Mevalonate Kinase Deficiency. Medicine (Baltimore). 2016;95(11):e3027-e.
21. Bodar EJ, Kuijk LM, Drenth JP, van der Meer JW, Simon A, Frenkel J. On-demand anakinra treatment is effective in mevalonate kinase deficiency. Ann Rheum Dis. 2011;70(12):2155-8.
22. Rossi-Semerano L, Fautrel B, Wendling D, Hachulla E, Galeotti C, Semerano L, et al. Tolerance and efficacy of off-label antiinterleukin-1 treatments in France: a nationwide survey. Orphanet J Rare Dis. 2015;10:19. Correspondência: Leonardo Oliveira Mendonça E-mail: leonardo.oliveira.mendonca@gmail.com Não foram declarados conflitos de interesse associados à publicação deste artigo.
23. De Benedetti F, Gattorno M, Anton J, Ben-Chetrit E, Frenkel J, Hoffman HM, et al. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes. N Engl J Med. 2018;378(20):1908-19.
24. ter Haar NM, Oswald M, Jeyaratnam J, Anton J, Barron KS, Brogan PA, et al. Recom-mendations for the management of autoinflammatory diseases. Ann Rheum Dis. 2015;74(9):1636‑44.
25. Rafiq NK, Lachmann H, Joensen F, Herlin T, Brogan PA. Tocilizumab for the Treatment of Mevalonate Kinase Deficiency. Case Rep Pediatr. 2018;2018:3514645.
26. De Leo L, Marcuzzi A, Decorti G, Tommasini A, Crovella S, Pontillo A. Targeting farnesyl-transferase as a novel therapeutic strategy for mevalonate kinase deficiency: In vitro and in vivo approaches. Pharmacol Res. 2010;61(6):506-10.
27. Tricarico PM, Girardelli M, Kleiner G, Knowles A, Valencic E, Crovella S, et al. Alendro-nate, a double-edged sword acting in the mevalonate pathway. Mol Med Rep. 2015;12(3):4238-42.
28. Cantarini L, Vitale A, Magnotti F, Lucherini OM, Caso F, Frediani B, et al. Weekly oral alendronate in mevalonate kinase deficiency. Orphanet J Rare Dis. 2013;8:196.
29. Neven B, Valayannopoulos V, Quartier P, Blanche S, Prieur AM, Debré M, et al. Allogeneic Bone Marrow Transplantation in Mevalonic Aciduria. N Engl J Med. 2007;356(26):2700-3.
30. Chaudhury S, Hormaza L, Mohammad S, Lokar J, Ekong U, Alonso EM, et al. Liver Transplantation Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Atypical Mevalonic Aciduria. Am J Transplant. 2012;12(6):1627-31.
31. Giardino S, Lanino E, Morreale G, Madeo A, Di Rocco M, Gattorno M, et al. Long-term outcome of a successful cord blood stem cell transplant in mevalonate kinase deficiency. Pediatrics. 2015;135(1):e211-5.
32. Li Cavoli G, Passantino D, Tortorici C, Bono L, Ferrantelli A, Giammarresi C, et al. Renal amyloidosis due to hyper-IgD syndrome. Nefrologia. 2012;32(6):865-6.
Submetido em:
11/05/2020
Aceito em:
12/09/2020
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email